Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhi-Yong Huang has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Erlei Zhang

    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    14 shared publications
  • Er-Lei Zhang

    10 shared publications
  • Tong Yuan

    Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    10 shared publications
  • Xing Lv

    Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    10 shared publications
  • Zun-Yi Zhang

    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    8 shared publications
  • Erlei Zhang

    7 shared publications

Latest Publications

  • Open Access

    Castleman disease combined with myasthenia gravis: A case report

    by Pengbo Zhang, Ronghua Zhu, Yi Zhou, Zunyi Zhang, Zhiyong Huang

    Castleman disease (CD) is a rare lymphoproliferative disorder of uncertain etiology. Although it is associated with various diseases, including Kaposi’s sarcoma, paraneoplastic pemphigus, and POEMS syndrome, its coexistence with myasthenia gravis (MG) remains exceedingly rare. To date, only a few studies have been conducted on this topic. Here, we report a rare case of MG combined with CD and provide a narrative review of the relevant literature, focusing on the diagnostic challenges, current therapeutic approaches for CD, and the crucial role of preoperative MG-targeted therapy in reducing postoperative complications. Our report aims to enhance clinicians’ understanding of this uncommon disease and emphasize the importance of an interdisciplinary treatment strategy for managing such complex cases.

  • Open Access

    Tumor-Induced Rewiring of Splenic Niches: from Immune Organ to Cancer Accomplice

    by Tong Yuan, Junjie Liu, Chunyu Zhang, Xing Lv, Guan Tan, Lin Xue, Erlei Zhang, Huifang Liang, Zhiyong Huang

    The spleen is the largest secondary lymphoid organ in humans. Beyond its classical role in clearance of senescent erythrocytes, it functions as a pivotal node in systemic immune surveillance. Emerging evidence indicates that tumor can remotely remodel splenic niches through a spectrum of soluble mediators, thereby accelerating tumor initiation and progression. Tumor-derived signals divert splenic hematopoietic stem and progenitor cells (HSPCs) toward myeloid- and erythroid-biased extramedullary hematopoiesis (EMH), expanding myeloid-derived suppressor cells (MDSCs) and erythroid progenitor cells (EPCs) that collectively foster immune evasion and metastatic cascades. Consequently, splenic resident immune cells, stromal cells and EMH-related pathways have surfaced as actionable therapeutic targets. In parallel, bidirectional crosstalk between the autonomic nervous system and splenic immunity fine-tunes homeostasis, systemic inflammation and antitumor responses—fueling rising interest in splenic neuromodulation as a therapeutic strategy. In addition, spleen-targeted nanoplatforms are emerging as promising tools to deliver immunomodulatory payloads with improved precision. Nonetheless, inherent structural and functional disparities between human and murine spleens complicate clinical translation of pre-clinical findings. This review provides a concise overview of human lymphoid organs and their functions, with a particular focus on splenic anatomy, cellular composition, and neural regulation. It further delineates tumor-induced splenic rewiring and discusses the prospects of exploiting the spleen as both a biomarker and a therapeutic target in oncology.


  • Open Access

    Prognostic model for unresectable hepatocellular carcinoma treated with transarterial therapy plus TKIs and anti-PD-1 antibodies

    by Tong Yuan, Junjie Liu, Xing Lv, Guan Tan, Ronghua Zhu, Yi Zhou, Pengbo Zhang, Lin Xue, Chunyu Zhang, Zhiyong Huang

    Transarterial therapy, including transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC), has long been a cornerstone in t


  • Open Access

    Impact of Cytokeratin 19 Expression on the Outcomes of Unresectable Hepatocellular Carcinoma Treated with Targeted Therapy and Immunotherapy: A Propensity Score Matched Analysis

    by Junjie Liu, Tong Yuan, Xing Lv, Guan Tan, Lin Xue, Zhiyong Huang

    Background: Cytokeratin 19 (CK19) serves as a significant prognostic indicator for hepatocellular carcinoma (HCC). However, it is uncertain if CK19 expression influences the prognosis and effectiveness of treatment in patients undergoing targeted therapy and immunotherapy for unresectable HCC. This study aimed to evaluate the prognostic value of CK19 expression in this patient population. Methods: Patients with unresectable HCC who received combined targeted therapy and immunotherapy between January 2021 and December 2023 were retrospectively analyzed in this study. CK19 expression in tumor biopsy samples from patients before treatments were identified using immunohistochemistry. Propensity score matching (PSM) was conducted in a 1:2 ratio to balance baseline features between the CK19-positive and CK19-negative groups. Survival outcomes were analyzed using the Kaplan-Meier method along with the Cox regression model. Treatment response was evaluated based on mRECIST criteria. Results: A total of 247 patients were included, and 126 were selected after-PSM (43 CK19-positive, 83 CK19-negative), with balanced baseline characteristics. After PSM, the CK19-negative group had a markedly prolonged median OS compared to the CK19-positive group (42.2 months vs 15.6 months, p < 0.001), along with an extended median PFS (28.9 months vs 7.3 months, p < 0.001). The ORR was significantly higher in the CK19-negative group than in the CK19-positive group (59.0% vs 18.6%, p < 0.001), and the DCR was also superior (96.4% vs 79.1%, p = 0.005). Multivariate Cox analysis found CK19 expression as an independent factor predicting OS and PFS. Conclusion: In patients with unresectable HCC undergoing targeted therapy and immunotherapy, CK19 expression correlated with poorer survival outcomes and diminished therapeutic response. CK19 may serve as a valuable biomarker for prognosis and treatment stratification in advanced HCC, and CK19 screening may be incorporated into clinical trial stratification and clinical decision-making.


  • Machine learning prediction of perineural invasion in intrahepatic cholangiocarcinoma

    by Guan Tan, Wen-Qiang Wang, Tong Yuan, Jun-Jie Liu, Zhen-Hui Xie, Zun-Yi Zhang, Zhi-Yong Huang


  • Open Access

    Liver resection for hepatocellular carcinoma with vascular invasion: Current insights and future perspectives

    by Tong Yuan, Junjie Liu, Xing Lv, Erlei Zhang, Zhiyong Huang

    The role of liver resection (LR) in patients with hepatocellular carcinoma (HCC) with vascular invasion (VI) remains controversial due to the inconsistent survival outcomes reported across different studies. In recent years, with breakthroughs in targeted therapy and immunotherapy for the treatment of advanced HCC, attempts to improve the surgical treatment outcomes of HCC with VI through neoadjuvant or adjuvant therapy have become an important research focus. This article reviewed the relevant literature published in recent years and systematically analyzed studies regarding LR in the treatment of HCC patients with VI and their outcomes. Based on previous studies, VI exhibits systemic characteristics. Despite the use of various surgical methods to resect the tumor or attempt to improve treatment efficacy by expanding the extent of LR, improving the surgical outcomes of HCC with VI has been problematic. Scientifically determining the extent of LR while fully preserving liver function, combining local and systemic therapies before and after surgery, and exploring more effective adjuvant treatment methods are important for further improving the efficacy of LR for HCC with VI.


  • Open Access

    Impact of intraperitoneal lavage with lobaplatin on survival in patients undergoing hepatectomy for ruptured hepatocellular carcinoma

    by Xing Lv, Rong-Hua Zhu, Gui-Bao Ji, Jian Li, Wen-Qiang Wang, Jin-Lin Wang, Bin-Yong Liang, Er-Lei Zhang, Zhi-Yong Huang

    Intraoperative intraperitoneal lavage with lobaplatin is widely used in the treatment of colorectal and gastric cancers. This study aimed to explore the efficacy of lobaplatin lavage in patients with ruptured hepatocellular carcinoma (HCC) administered radical hepatectomy. Ruptured HCC patients who underwent hepatectomy between September 2007 and March 2022 were divided into the distilled water lavage and lobaplatin lavage groups. Survival curves for RFS and OS were generated by the Kaplan-Meier method and compared by the log-rank test using Propensity Score Matching (PSM). Cox regression analysis was conducted to identify independent prognostic factors of RFS and OS. This study included 201 patients, with 114 cases (89.1%) in the distilled water lavage group and 55 cases (75.3%) in the lobaplatin lavage group experiencing recurrence, and 95 (74.2%) and 44 (60.3%) patients died in the distilled water lavage and lobaplatin lavage groups, respectively during the follow-up period. After PSM, 1-, 2-, 3-year RFS rates were 38.6%, 21.1%, 10.5% and 57.9%, 40.4%, 26.3% in the distilled water lavage and lobaplatin lavage groups, respectively (P = 0.001). 1-, 2-, 3-year OS rates were 56.1%, 40.4%, 33.3% and 89.5%, 63.2%, 43.9% in the distilled water lavage and lobaplatin lavage groups, respectively (P = 0.001). Multivariable Cox regression indicated that lobaplatin lavage may improve RFS (HR = 0.524, 95% CI: 0.354–0.775;P = 0.001) and OS (HR = 0.524, 95% CI: 0.350–0.783;P = 0.002). Intraoperative lobaplatin lavage improves RFS and OS in patients with ruptured HCC after hepatectomy. TJ-IRB202403002, 2024-04-26, retrospectively registered.


  • Open Access

    Autologous Tumor-Infiltrating Lymphocyte Infusion plus Anti-Programmed Cell Death Protein 1 Therapy to Cure Advanced Hepatocellular Carcinoma following Palliative Hepatectomy

    by Tian Xia, Tong Yuan, Li-Jun Chen, Chang-Li Wang, Er-Lei Zhang, Bin-Yong Liang, Zun-Yi Zhang, Ming-Wei Wang, Xiao-Ping Chen, Zhi-Yong Huang

    Introduction: Adoptive cell therapy derived from autologous tumor-infiltrating lymphocytes (TILs) has demonstrated promising therapeutic efficacy in several cancers. However, its possible synergistic effects with anti-PD-1 therapy in advanced hepatocellular carcinoma (aHCC) remain unexplored. This study aimed to investigate the efficacy of TIL infusion combined with anti-PD-1 therapy for aHCC. Case Presentation: Referring to the current protocol of our clinical trial (NCT03658785), 2 patients with HCC at BCLC stage C were enrolled to receive autologous TIL infusion combined with anti-PD-1 therapy. They underwent unplanned palliative tumor resection to alleviate pain caused by tumor rupture prior to receiving TIL infusion plus anti-PD-1 therapy. Long-term outcomes and treatment-related adverse events were evaluated. Throughout the entire treatment process, both patients experienced only mild symptoms. Notably, both patients achieved complete responses to the treatment and have remained tumor-free for 2 and 4 years, respectively. Conclusion: Autologous TIL infusion combined with anti-PD-1 therapy is a safe and feasible strategy for patients with aHCC. Palliative hepatectomy with maximal tumor burden reduction may significantly improve its efficacy and even results in cure for aHCC patients.


  • Open Access

    NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma

    by Jiajia Du, Zhiyong Huang

    A high baseline NLR is associated with a poor prognosis of immunotherapy in patients with advanced HCC. As anti-tumour immune activation takes time, early dynamic changes in NLR may serve as a biomarker for predicting immunotherapy response. We conducted a retrospective study in which we enrolled 209 patients with aHCC who received ICIs (training cohort: N = 121, validation cohort: N = 88). In the training cohort, we categorized the patients based on the early changes in their NLR. Specifically, we defined patients as NLR Stable-Responder, NLR Responder and NLR Non-Responder. We compared the outcomes of these three patient groups using survival analysis. Additionally, we shortened the observation period to 6 weeks and validated the findings in the validation cohort. In the training cohort, early dynamic changes in NLR (HR 0.14, 95%CI 0.03–0.65, p = 0.012, HR 0.19, 95%CI 0.07–0.54, p = 0.002; HR 0.21, 95%CI 0.10–0.42, p < 0.001, HR 0.40, 95%CI 0.23–0.69, p = 0.001), PD-L1 < 1% (HR 5.36, 95%CI 1.12–25.66, p = 0.036; HR 2.98, 95%CI 1.51–5.91, p = 0.002) and MVI (HR 3.52, 95%CI 1.28–9.69, p = 0.015; HR 1.99, 95%CI 1.14–3.47, p = 0.015) were identified as independent predictors of OS and PFS. In the validation cohort, when the observation period was reduced to 6 weeks, early NLR changes still have predictive value. Early dynamic changes in NLR may be an easily defined, cost-effective, non-invasive biomarker to predict aHCC response to ICIs.


  • Open Access

    The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy

    by Jiajia Du, Erlei Zhang, Zhiyong Huang

    Background: Targeted and Immunotherapy has emerged as a new first-line treatment for advanced hepatocellular carcinoma (aHCC). To identify the appropriate targeted and immunotherapy, we implemented next generation sequencing (NGS) to provide predictive and prognostic values for aHCC patients.Methods: Pretreatment samples from 127 HCC patients were examined for genomic changes using 680-gene NGS, and PD-L1 expression was detected by immunohistochemistry. Demographic and treatment data were included for analyses of links among treatment outcomes, drug responses, and genetic profiles. A prognostic index model for predicting benefit from treatment was constructed, taking into account of biomarkers, including TP53, TERT, PD-L1, and tumor mutation burden (TMB) as possible independent prognostic factors.Results: The multivariate Cox regression analyses showed that PD-L1≥1% (HR 25.07, 95%CI 1.56 - 403.29, p=0.023), TMB≥5Mb (HR 86.67, 95% CI 4.00 - 1876.48, p=0.004), TERT MU (HR 84.09, 95% CI 5.23 - 1352.70, p=0.002) and TP53 WT (HR 0.01, 95%CI 0.00 - 0.47, p=0.022) were independent risk factors for overall survival (OS), even after adjusting for various confounders. A prognostic nomogram for OS was developed, with an area under the ROC curve of 0.91, 0.85, and 0.98 at 1-, 2-, and 3- year, respectively, and a prognostic index cutoff of 1.2. According to the cutoff value, the patients were divided into the high-risk group (n=29) and low-risk group (n=98). The benefit of targeted and immunotherapy in the low-risk group was not distinguishable according to types of agents. However, treatment of Atezolizumab and Bevacizumab appeared to provide longer OS in the high-risk group (12 months vs 9.2, 9, or 5 months for other treatments, pTERT, and TP53 can identify aHCC patients who would benefit from targeted and immunotherapy, providing insights for the personalized treatment of HCC.